The Dow Jones Industrial Average comprises 30 blue chip stocks that investors often regard as a proxy for the overall economy. Amidst that prominence, all but two of the 30 components return cash to s
UNH is deeply oversold, with consensus expectations set extremely low ahead of Q2, creating a setup for a relief rally on even modestly negative news. Guidance withdrawal has fueled uncertainty, but r
Since early May, insider buying activity has surged at three major companies. Together, top executives and influential insiders have invested more than $170 million of their own money, sending a stron
After briefly dipping into bear market territory just three months ago, the S&P 500 (^GSPC 0.35%) has quickly managed to recover, rising 6.6% year to date (as of this writing). But not all stocks in t
The health insurer now expects 2025 earnings of just $30 a share, citing ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid.
A majority of publicly traded US health insurers are expected to post QoQ declines in revenue and net income in Q2, according to an S&P Global Market Intelligence analysis of sell-side analyst forecas

UnitedHealth: Profitable, Growing, Cheap

05:41pm, Wednesday, 16'th Jul 2025
UnitedHealth stock has gotten cheap this year due to a slew of PR issues. Some of these issues pertain to the company's handling of health insurance claims. The company is profitable enough and has a
The market often misinterprets price declines as value. For Elevance Health, I see a disconnect between market cap and long-term earnings potential. Health sector valuations have dropped sharply, but
NEW YORK, July 16, 2025 /PRNewswire/ -- A new report from Gimme Credit's Senior Bond Analyst, Terri Cancelarich highlights growing pressures facing U.S. health insurers amid regulatory scrutiny and fu
CVS Health's Caremark business signed a new pharmacy benefits contract with the California Public Employees' Retirement System, known as Calpers.

UnitedHealth Group's Huge Day

06:34pm, Tuesday, 15'th Jul 2025
Headwinds galore from regulatory scrutiny, Medicare Advantage costs, and management changes, but insiders are buying, and the valuation is historically cheap. Q2 earnings are likely to be the trough.
After a 40% YTD plunge, UnitedHealth is deeply oversold and undervalued. All the bad news is priced in, creating a compelling risk/reward setup. The return of proven former CEO Stephen Hemsley signals
In the latest trading session, UnitedHealth Group (UNH) closed at $300.58, marking a -1.16% move from the previous day.
UNH relies on its growing commercial insurance business as pressures from Medicare mount and industry headwinds persist.
Health insurer Elevance Health Inc. ELV is scheduled to release its second quarter 2025 financial results on July 17.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE